Apr 13, 2026
Allogene Therapeutics (ALLO) Stock Soars 41% Following Breakthrough CAR T-Cell Trial Results
Allogene (ALLO) stock jumped 41% on promising ALPHA3 trial data showing 58% MRD clearance with no CAR T toxicities. Baird ups target to $9.
The post Allogene Therapeutics (ALLO) Stock Soars 41% Following Breakthrough CAR T-Cell Trial Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 8 hours ago
Apple (AAPL) Stock: Q2 Earnings Beat Expectations with 17% Revenue Jump and $100...
- 11 hours ago
Alphabet (GOOGL) Stock Soars 10% as Q1 Results Demolish Analyst Projections
- 12 hours ago
Amazon (AMZN) Stock Dips After Strong Q1 Earnings — What Spooked Investors?
- 12 hours ago
CoreWeave (CRWV) Stock Climbs 8% Despite $45M Insider Share Dump
- 12 hours ago
Nvidia (NVDA) Tumbles 4% Amid Rising Competition from Google and Amazon Custom C...